The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ABUS | +42.24% | +12.24% | +2.34% | -30% |
| S&P | +12.65% | +84.17% | +12.99% | +469% |
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
After a strong start to 2023, the virology-focused biopharma company has hit a regulatory speed bump.
The company could have great prospects if its hepatitis B virus therapy is successful in clinical testing.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.53M | -60.5% |
| Gross Profit | $0.52M | -48.4% |
| Gross Margin | 97.92% | 23.0% |
| Market Cap | $870.31M | 19.7% |
| Market Cap / Employee | $19.78M | 0.0% |
| Employees | 44 | -39.7% |
| Net Income | -$7.74M | 60.7% |
| EBITDA | -$8.28M | 51.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $22.41M | -29.6% |
| Accounts Receivable | $0.91M | -43.7% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $4.08M | -35.2% |
| Short Term Debt | $0.53M | 13.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -35.50% | 15.8% |
| Return On Invested Capital | -54.03% | 18.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$5.82M | 72.0% |
| Operating Free Cash Flow | -$5.82M | 72.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 5.80 | 6.81 | 7.47 | 10.49 | 53.67% |
| Price to Sales | 100.66 | 103.95 | 38.56 | 59.61 | -44.77% |
| Price to Tangible Book Value | 5.80 | 6.81 | 7.47 | 10.49 | 53.68% |
| Enterprise Value to EBITDA | -43.45 | -43.98 | 260.62 | -94.37 | 166.57% |
| Return on Equity | -68.8% | -79.0% | -52.8% | -45.9% | -32.34% |
| Total Debt | $6.12M | $5.60M | $5.00M | $4.61M | -31.87% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
